Bayer's regorafenib gets orphan drug designation

Bayer HealthCare Pharmaceuticals' investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the FDA. Regorafenib is not approved by the FDA, the European Medicines Agency or other health authorities. Bayer release